SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending due to volatile price action and intense debate surrounding the reopening of the Strait of Hormuz following a new U.S.-Iran memorandum of understanding. The community is heavily divided, with bears pointing to increased tanker traffic and Iranian sanctions relief as signs of a supply-driven price collapse, while bulls are actively discussing potential short squeezes and the impact of depleted global oil reserves.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors anticipate a major catalyst from the final survival events of its Phase 3 REGAL trial for GPS, while the stock faces significant volatility driven by a massive short squeeze. The community is intensely debating whether this momentum will trigger a potential buyout, with bulls pointing to revolutionary clinical data and shorts facing severe margin pressure due to extremely high borrow costs.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is experiencing significant volatility as market participants debate the timing of potential regulatory clarity and the impact of institutional integration on price stability. The community remains deeply divided, with some investors accumulating through the downturn while others express frustration over extended periods of consolidation and ongoing selling pressure.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense bearish sentiment as investors express concerns over the company's aggressive financing model and the sustainability of its dividend obligations amid a dip in Bitcoin prices. The stock's decoupling from Bitcoin performance has fueled community debates regarding the risks of shareholder dilution and the underlying stability of its enterprise strategy.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a recent negative opinion from the EMA, which has prompted plans for an appeal and re-examination through an independent expert panel. Community discussion is focused on the potential for a regulatory reversal, the significance of the upcoming US J-code implementation for Yartemlea, and frustration regarding recent executive departures and the company's communication strategy.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent Biosolutions is currently a focus for investors as the company executes a multi-year turnaround strategy under CEO Joe Papa, highlighting recent strategic manufacturing partnerships and expanded international approvals for its ACAM2000 vaccine. Community discussion is heavily divided, with some investors betting on a potential short squeeze fueled by significant short interest and contract-based upside, while skeptics remain focused on the company's debt profile and the volatility of its public health-dependent business model.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is drawing significant community debate as traders weigh potential for a massive turnaround against concerns over persistent insider selling, ongoing legal scrutiny regarding its financial disclosures, and the company's heavy reliance on secondary lending. While bullish investors draw parallels to past recovery stories and anticipate upside from expanding inventory and market reach, bears maintain high conviction in a correction, citing unsustainable valuation metrics and the absence of meaningful insider purchases to support the long-term thesis.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust is trending amidst intense community debate over whether the asset is entering a prolonged "crypto winter" or remains a long-term hedge against fiat devaluation. Investors are closely monitoring massive capital outflows from spot ETFs and diverging analyst perspectives on whether recent price volatility signals an imminent market bottom or a deeper cyclical correction.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is experiencing significant volatility and a sharp sell-off following the release of Phase 3 maintenance trial data for its ulcerative colitis drug, obefazimod, which triggered concerns over reported malignancy cases. While the community is debating whether these safety signals are statistically significant or merely background noise, many are viewing the price drop as an overreaction and a potential buying opportunity for a buyout candidate with strong efficacy results.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund ($XLE) is currently experiencing high volatility driven by deep uncertainty surrounding the Strait of Hormuz, as market participants debate whether recent de-escalation headlines signal a true energy supply reset or merely temporary geopolitical maneuvering. Community sentiment remains polarized, with traders actively debating the structural impact of record-low inventories and shifting trade routes against the persistent threat of further regional escalation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results

Equity

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Why Is Dianthus Therapeutics Stock Trading Higher On Friday?

Dianthus reports 75% responder rate for claseprubart in CIDP, while analysts say Sanofi's riliprubart faces rising risks after MOBILIZE.read more...

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline

Dianthus Therapeutics (DNTH) Appears Attractive Amid Solid Product Pipeline...

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish...

Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price

Wedbush raised their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an 'outperform' rating in a report on Wednesday...

Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts...

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +27.04% and -15.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics (DNTH) to Release Earnings on Monday

Dianthus Therapeutics (NASDAQ:DNTH) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-11-dianthus-therapeutics-inc-stock...

Short Interest in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Decreases By 27.6%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling...

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Dianthus Therapeutics Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$95.35
Prev Close	$91.57
Open	$91.80
Dividend Yield	0.00%
50-Day Moving Average	$86.61
Beta	1.09
Avg. Volume	532,574.66
PE Ratio	-22.13

52-Week High	$96.50
52-Week Low	$17.27
Market Capitalization	$5.21B
EPS (Annual)	-$4.20
Price to Book	4.16
Revenue Per Employee	$22,130.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

DNTHDianthus Therapeutics Inc

Latest DNTH News